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Next generation sequencing (NGS) coupled with sophisticated bioinformatics tools yields an unprecedented
amount of information regarding tumor genetics, with the potential to reveal insights into tumor behavior.
NGS and other multiplex genomic assays are rapidly spilling from the laboratory into the clinic through
numerous commercial and academic entities. This raises the important question as to whether we are ready
to use these data in clinical decision-making. While genetic lesions are clearly targeted by a new generation
of biological cancer therapies, and certain regulatory approvals are actually coupled to single gene assays, we
still do not know if the vast information on other genomic alterations is worth the added cost, or even worse,
the inappropriate and unproven assignment of patients to treatment with an unapproved drug carrying potentially
serious side effects. On the other hand, the trend toward a precision medicine pathway is clearly accelerating, and
clinical trials validating pathway-driven personalized cancer therapeutics will be necessary in both the community
and academic settings. Lower cost and wider availability of NGS now raises a debate over the merit of routine tumor
genome-wide analysis.
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Debu Tripathy (Figure 1)
As with most new technologies and treatments, mo-
lecular diagnostics are entering the oncology arena in
phases. However, these phases are not fully evidence-
based or scientifically driven – they are somewhat
organic as physician and patient interest always seems to
be a step or two ahead of the data. The concept of
‘precision medicine’, defined as therapy that is persona-
lized to unique disease and host characteristics, has
taken huge leaps in the cancer field with the advent of
next generation sequencing (NGS) [1,2]. NGS encom-
passes several technologies that generate gene sequence as
well as copy number alterations and translocation of
numerous genes. However, as pointed out by Dr. Robson,
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unless otherwise stated.still relies on single gene analysis, such as EGFR mutations
and ALK rearrangements for lung cancer, BCR-ABL trans-
location (both presence and transcript quantification) for
chronic myelogenous leukemia (CML) and HER2 amplifi-
cation for breast cancer [3-6]. The advantages of NGS are
primarily the brute force of sequencing just about all
expressed genes depending on the details of the platform,
as well as the great ‘depth’, that is the number of ‘reads’
that allows for the detection of mutations that may be
seen in only a fraction of cells (but are potentially the
most dangerous ones). A disadvantage is the level of
noise – mutations that may not be ‘drivers’ or may not
be ‘actionable’, in that they do not clearly lend them-
selves to specific effective therapies. Several approaches
have been devised to distinguish random (or ‘passenger’)
mutations from true drivers, including direct testing of
the genetic lesions in preclinical models or bioinforma-
tics approaches that model the effects from the mutation
sites and downstream biological pathways. We can also
assume that more frequent mutations are those selected
above the much rarer random ones due to theirl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Debu Tripathy, MD is Professor of Medicine and
Co-Leader of the Women's Cancer Program at University of
Southern California/Norris Comprehensive Cancer Center and
holds the Priscilla and Art Ulene Chair in Women’s Cancer.
His area of clinical research interest is novel therapeutics in breast
cancer, specifically, growth factor receptor pathway targeting as well as
biomarkers that predict sensitivity and resistance. He is also part of a
trans-disciplinary breast specialty team dedicated to patient-centered
and personalized approaches to care, with an emphasis on translational
clinical trials.
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resistance in the case of those that may arise after
treatment). Even mutations that can be biologically
confirmed as mediators of malignancy and metastasis phe-
notypes and for which active drugs exist may not be clini-
cally useful. This is evidenced by the successful targeting of
BRAF mutation (V600E)-associated melanoma with BRAF
and downstream MEK inhibitors, but the lack of efficacy in
BRAF-mutated colorectal cancer, perhaps due to more
genomic alterations and resultant bypass pathways [7,8].
NGS can generate results quickly since millions of
pieces of small pieces of DNA are read in parallel. But
tiling, or aligning the reads to generate interpretable
results, requires complex bioinformatics support and a
significantly longer time. For many tumor types, NGS has
no proven benefit, although the theoretical advantage isthat it may identify a clinical trial or even drug approved
for a different cancer type that MIGHT be helpful.
Accordingly, for today’s clinical practice, single gene assays
suffice. However, as NGS become cheaper, it may be a
simpler way to perform diagnostics on the small number
of tumors in which several mutations, translocations or
deletions are of proven benefit in decision-making, such
as lung cancer or hematological malignancies. It also
requires less tissue than multiple single gene tests. Also,
customized panels for more commonly mutated genes in
a specific cancer are becoming available that may offer
focused multi-gene testing at a lower cost and yielding
fewer ‘uninterpretable or unactionable’ findings.
NGS can also be applied to germline testing to detect
heritable cancer susceptibility gene mutations and va-
riants. It can also be helpful in the interpretation of tumor
NGS results by excluding inherited variants that may be
mono-allelic in the tumor. For familial genetic testing,
NGS or multi-gene panel testing is being increasingly used
as sequencing costs drop and can be informative in the
setting of strong family histories without mutations seen
in more common predisposition genes. In one series of
patients, with a family history of breast cancer but no
mutation seen in BRCA 1 or 2, a 42-gene panel assay
found additional findings in 15 of 141 patients (11%), most
of whom had breast cancer, with germline mutations/vari-
ants seen in ATM, BLM, CDH1, CDKN2A, MUTYH,
MLH1, NBN, PRSS1 and SLX4 genes [9]. This technology
could therefore address the need to lower cost and expand
the scope of gene susceptibility testing, but it also creates
clinical dilemmas in the management of the carriers of
these gene anomalies for whom we do not fully under-
stand the natural history and cannot provide lifetime
cancer risk estimates.
So when should we be using NGS or multi-gene testing?
From the standpoint of clinical utility, the bar is quite
high, and has clearly not been reached – that would
require the demonstration that the actions based on the
test actually result in clinical benefit compared to deci-
sions made without its use. At this time, single gene
assays meet that criteria, but not NGS. In fact, we have
not even excluded harm – an inappropriate or harmful
decision from acting on a result of NGS given the vast
amount of information contained in the result and the
paucity of knowledge for most of the ‘targets’ listed. As
an example, a recent trial for patients with advanced
breast cancer that performed array comparative genomic
hybridization for copy number variation and gene
sequencing (AKT and PI3KCA only) and then assigned
them to a panel of drugs that were known or presumed
to address the genetic lesions. Of 423 patients enrolled,
biopsies were obtained in 297, with genomic analysis
feasible in 283, genomic alterations identified in 195,
Figure 2 Kathleen Harnden, MD is a senior fellow at Duke
University Medical Center. She graduated from Keck School of
Medicine at University of Southern California and completed her
internship and residency at Duke University Medical Center. Her
research interests include breast cancer genetics and clinical trials in
metastatic breast cancer.
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treated with 16 different targeted regimens and evaluable
for response, only 4 had objective responses and 9 had
stability of disease [10]. These results illustrate the prema-
turity of using broad-based molecular testing routinely,
but do point to the promise that these numbers can
significantly improve with more comprehensive analysis
and more experimental drugs available. Also, disease types
with more ‘druggable’ targets, such as lung cancer and
hematological malignancies, could yield different results
and several prospective consortia are testing this approach.
Drs. Harnden and Blackwell appropriately emphasize that
as more patients and their treating oncologists are able
to access a growing number of mutation-guided clinical
trials, NGS may be justifiable – ideally as a formal part of
such trials.
The future of genomically targeted cancer therapy will
not only include NGS, but other high throughput tech-
nologies such as RNA sequencing that provides quanti-
tative gene expression as well as mutational status and
can also analyze micro- and noncoding RNAs that
modulate gene expression. Proteomic analysis can also
provide functional information that lends itself to drug
selection. Also, genomic analysis after treatment
progression can be very productive as demonstrated
with studies of imatinib-resistant CML harboring the
difficult-to-treat T315 resistance-associated mutation in
BCR-ABL and resistance-associated mutations in EGFR,
such as T790M in lung cancer, where this knowledge
has led to the development of new therapeutics (ponati-
nib approved for CML and several drugs in testing for
EGFR-kinase inhibitor-refractory lung cancer) [11,12].
Importantly, a growing body of information regarding
mutational analysis in large populations in the context of
clinical outcome and response to therapies will assemble a
more robust understanding of cancer genomics and
systems biology that can elucidate critical vulnerabilities
that can be tackled with specific targeted drugs, or
more likely, combinations of drugs [13,14]. The availabi-
lity of portals for patients and physicians to understand
better the nature and consequences of genomic alte-
rations, available therapies and open clinical trials (such as
MyCancerGenome) [15] will greatly aid in clinical deci-
sions and trial referral. Finally, large trials with numerous
available targeted drugs are planned, including the NCI
Match demonstration trial across all solid tumors and the
MASTER protocol as a regulatory approval pathway for
second-line squamous cell lung cancer treatment [16].
Altogether, this spells for a bright future for this still nas-
cent field that will lead to comprehensive and precision
molecular cancer therapeutics.
Competing interests
The author declares that he has no competing interests.Tumor mutation profiling in breast cancer is
ready for routine use in the clinic
Kathleen Harnden and Kimberly Blackwell
(Figures 2 and 3)
The foremost priority in cancer research is persona-
lized treatment approaches offering the promise of
more effective and better tolerated therapies. One major
step towards offering personalized therapy is the use of
genomic mutational analysis to help drive decision making
in the clinic. Technologies such as NGS offer comprehen-
sive analysis of specific mutations present in each patient’s
breast cancer. The argument to include NGS in clinical
decision making is based on several concepts including:
1) Actionable mutations are well described in the lite-
rature and targeted therapies are now available in the
approved or trial setting; 2) Mutations might provide pre-
dictive capabilities for certain types of standard and
experimental therapies and, therefore, offer an enrichment
strategy in designing clinical trials; and 3) Mutations
might offer prognostic and/or predictive information in
certain types of breast cancer, such as HER2+ and triple
negative breast cancer. We will now discuss each of these
points in some detail.
There are many biologically meaningful and, therefore,
actionable mutations described in cancer with currently
available therapeutic options. These mutations are not
confined to specific tissue origins. Instead, these mutations
define subgroups of cancer in ways that we do not
currently use clinically. The number of mutations with
targeted therapies in breast cancer is ever increasing and
currently includes genes such as poly (ADP-ribose) poly-
merase (PARP) (PARP inhibitors), p53 (vaccine therapy,
gene therapy, Wee-1 inhibitors, Kevetrin), estrogen recep-
tor alpha (ESR1) (alternative endocrine therapies), JAK1
Figure 3 Kimberly Blackwell, MD is professor of medicine and
assistant professor of radiation oncology at Duke University
Medical Center and director of the breast cancer program at
the Duke Cancer Institute, where she oversees all basic and
translational research programs involving breast cancer
patients. She has played a major role in two recently approved
breast cancer drugs, lapatinib and T-DM1, both of which were
studied in her laboratory and developed in trials in which she served
as principal investigator.
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There are also new actionable mutations on the horizon
that are not well described in breast cancer with deve-
loping targeted therapies, including mutated genes such as
dynein (hsp90 inhibitors, HDAC inhibitors), MST1 (anti-
MST1 receptor antibodies), ROS-1 (inhibitors), HGF (anti-
bodies against c-met, c-met inhibitors), and ALDH8A1
(disulfiram). NGS empowers providers to identify and
exploit driving mutations in breast cancer biology and to
employ new real time therapeutic options in the clinic.
Additionally, NGS is ready for routine use in the onco-
logy clinic as it could create a redesign in the way patients
are enrolled in clinical trials. NGS identifies meaningful
mutations, allowing improved and more rigorous enroll-
ment in clinical trials. These actionable mutations allow
providers to transform standard treatment plans to indi-
vidualized approaches and match patients to clinical trials.
As NGS becomes more readily available and affordable, it
should allow for better enrichment strategies for enroll-
ment into clinical trials. To use NGS to enrich trial popu-
lations should be a very attractive idea to both study
sponsors and patients.An example of using NGS for trial enrichment is
found in the SAFIR01 study. In a prospective trial of
more than 400 breast cancer patients, André et al. found
a targetable genomic alteration in 46% of patients [10].
Of these patients, 25% had treatment driven by geno-
mics and 28% of the patients who were treated with
genomic-driven therapy had an objective response or
stable disease for up to 10 months. In this heavily pre-
treated population of patients, the ability to find action-
able targets in nearly half of the patients and provide
benefit to the nearly 1/3 who received the treatment is
clinically meaningful. Additionally, clinical trials of tar-
geted agents in which patients would have been deemed
ineligible using standard testing methods are now being
designed to include NGS [18]. Patients with activating
mutations of HER2 who were considered ineligible for
standard HER2 based therapy now have new clinical trial
options and therapeutic options based on sequencing
results [18].
Another example of how NGS can enrich trial popula-
tions is found in the NCI MATCH (Molecular Analysis
for Therapy Choice) study [16]. In this study, 1,000 pa-
tients with common and rare tumors will be enrolled for
NGS at the time of progression to elucidate resistance
mechanisms and to choose single agent or combination
targeted therapy for these patients. There are currently
20 ‘arms’ of the study and more than 40 targeted agents
pledged for use. The techniques, reliability and workflow
are currently being optimized to streamline the NGS
data for real time clinical impact.
A third reason that NGS is ready for the clinic is that
it could better define prognosis (prognostic value) or po-
tential compounds that have a higher likelihood of bene-
fiting patients (predictive value). Each specific oncogenic
event provides an opportunity for targeted therapy. If we
can identify a molecular profile associated with greater
therapeutic benefit we can prospectively select patients
accordingly. Similar to the increased benefit of platinum
therapy in metastatic triple-negative breast cancer in
BRCA 1/2 positive patients [19] and a poorer prognosis
in docetaxel and trastuzumab +/- pertuzumab therapy in
HER2 amplified metastatic breast cancer in patients with
a PIK3CA mutation [20], NGS can provide a foundation
on which to maximize clinical benefit of highly targeted
therapies based on tumor mutational signatures.
Finally, NGS could influence decision making in the
clinic in determining prognosis in certain subtypes of
metastatic breast cancer patients. O’Shaughnessy et al.
found that extraordinary responders to lapatinib with tras-
tuzumab primary-refractory inflammatory breast cancer
share a common cancer genotype [21]. These cancer
genotypes and their response phenotype can be elucidated
for innumerable therapy regimens and used to make
predictably beneficial treatment decisions in the clinic
Figure 4 Mark Robson, MD is an Attending Physician of the
Clinical Genetics and Breast Medicine Services in the
Department of Medicine at Memorial Sloan-Kettering Cancer
Center. His research is directed toward improving the integration
of genetic information into the clinical management of women with
breast cancer. He and his colleagues have conducted a number of
studies examining outcomes in women with hereditary breast
cancer to better define the risks and benefits of treatments such as
breast conserving therapy and adjuvant chemotherapy in this group.
He is currently conducting studies to evaluate the impact of
intensive screening or surgical prevention upon women's quality of
life and to develop new screening tools for breast cancer, such as
serum peptide profiling.
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Cancer Symposium identifying gene mutations associated
with progression free survival (PFS) in metastatic breast
cancer [26]. Patients with WNK1 mutations had a median
PFS of 1.4 months compared to 7.3 months (P = 0.03) in
those with the wild type gene. Conversely, patients with
mutated MST1 had improved PFS of 11.4 months com-
pared to 6.2 months (P = 0.04) with the wild type gene.
Likewise, several gene mutations conferred differences in
overall survival. This prognostic information, obtained
using NGS, could become incredibly valuable in counseling
patients and in selecting appropriate therapies.
Although many of the therapeutic implications of NGS
involve clinical trial participation, NGS is ready for the
clinic. Some clinicians would argue it already is in the
clinic. Our focus now should turn to bringing this revolu-
tionary, therapy-altering and prognostic technology to all
patients in an efficient, affordable way. In order to achieve
this goal, scientists, bioinformatics specialists, clinicians
and patients will need to work together to bring NGS to
its full capacity.
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Tumor mutation profiling is not ready for routine
use beyond the research setting
Mark Robson (Figure 4)
Cancer is a genetic disease, in the sense that the malig-
nant phenotype arises, in large part, as a result of muta-
tions in the DNA of the cancer cell. Massively parallel
NGS offers the opportunity to define the pattern of
genomic alterations in a patient’s cancer quickly and affor-
dably. This capability could, in theory, fulfill the promise
of ‘precision medicine’ and allow treatment tailored to the
specific drivers of the individual patient’s disease. This
promise has captured the imagination of oncology
professionals, and a number of commercial and academic
laboratories now offer tumor mutation profiling. Like any
new technology, however, tumor mutation profiling with
NGS is most appropriate for specific purposes. At this
point, NGS is a tool for oncology research and does not
yet have a place in routine clinical care.
There are three main ways that an oncologist could use
information about the pattern of mutations in a patient’s
cancer. First, he or she could use the information to select
a treatment that has been approved by regulatory autho-
rity for use in the setting of a particular genetic change.
Second, the oncologist could use the information to iden-
tify patient eligibility for clinical trials of new targetedagents. Finally, the oncologist could use the information
to select a targeted treatment for ‘off-study’ and ‘off-label’
use. At this time, it is not necessary to employ NGS for
the first purpose, and inappropriate to utilize NGS for the
last. There may be a limited role for NGS for the second
purpose, at least in academic medical centers with early
development programs, but in most clinical situations,
more directed testing is more appropriate.
There are increasing numbers of agents that are approved
for the treatment of cancers harboring specific genomic
alterations. The canonical example, of course, is the use of
imatinib in the treatment of chronic myelogenous leukemia
harboring the BCR/ABL rearrangement [27].A more recent
example is the remarkable success of BRAF inhibitors in
the treatment of malignant melanomas with BRAF V600E
mutations [28]. Tumor mutation profiling can identify
these mutations, of course, but the specific alterations
appropriate for treatment with approved agents are well-
defined, and there are usually specific companion diagnos-
tic assays. There is no obvious benefit to using a NGS assay
to identify an established mutation, and likely significant
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lar disease type, NGS profiling is not necessary.
At the other end of the spectrum is the hope that
NGS may identify a therapeutic target that would not
have been considered based on disease type, and that
this knowledge will allow the oncologist to select an ‘off
the shelf ’ treatment for a patient that will be superior to
a more traditional physician-selected therapy. While this
is the application that is the most logical in the popular
imagination, it is also the one that is the least supported
by data. Even if one identifies a mutation that confers
sensitivity in a particular disease, it may not predict
response in another context. An example is the relative
insensitivity of BRAF-mutant colon cancer to BRAF
inhibition, despite the presence of the same mutation that
confers sensitivity in melanoma [8]. The situation
becomes even more complicated when one attempts to
predict response based upon non-canonical alterations in
genes that could be plausible targets for existing drugs. If
the platform evaluates tumor DNA alone, any identified
sequence change may, in fact, be germ line (inherited) in
origin. The mere fact that a variation is rare does not
argue for pathogenic relevance, since most normal human
variation is common, and even protein-truncating muta-
tions are seen in the constitutional DNA of apparently
healthy people [29,30]. To identify sequence variants that
are present in tumor only, a number of laboratories now
sequence tumor and normal samples simultaneously, and
‘subtract’ the germ line sequence from the somatic se-
quence in order to identify those variants that are unique
to the tumor. However, even somatic variants may not be
causative. Such variants may not be functionally signifi-
cant, and the process of determining causality is both
complex and partly subjective despite the best efforts of a
number of groups to standardize the process of curation
[31]. Even if causative, the variant may not be directly
related to the cancer process (‘passenger’ rather than
driver’ mutation), in which case targeting the mutation
will not have an effect on the growth of the tumor.
Even if a sequence variant is somatic, functional and
related to the cancer process, targeting it may not be bene-
ficial because it may not be present in the metastases that
are threatening the patient. Genetic heterogeneity is an
enormous challenge, both as a possible substrate for the
development of resistance and as a source of variation
between primary and metastatic sites (as well as between
metastatic sites) [32]. Inadequate sampling may limit the
ability to delineate the actual genomic changes that are
most relevant to treatment.
Even if the variant is relevant in light of all of these con-
siderations, it may not be targetable. There may not be an
‘off the shelf ’ drug that can attack the vulnerability or
tumor context may limit response (as discussed previously
for BRAF inhibitors). Even if a drug is available, resistanceto single agent targeted treatment often evolves quickly in
solid tumors [33], and untested combinations of targeted
agents are extremely unwise without careful delineation of
toxicities in properly conducted clinical trials. Finally, even
if a particular genomic alteration is relevant and targetable,
the genomically-directed treatment may not be superior to
conventional therapy, and foregoing a proven approach in
favor of an unapproved targeted treatment may lead to
inferior outcomes. The comparison of genomically-directed
treatment to conventional therapy requires carefully
designed, innovative clinical trials such as the recently
announced Friends of Cancer Research-NCI Lung Cancer
Master protocol [16,34].
While tumor mutation profiling does not yet have a role
in determining treatment off-study, it may be a useful
means of identifying patients who are candidates for
studies of new genomically-directed therapies. At aca-
demic centers with extensive portfolios of new agents, it
may be productive to conduct routine tumor profiling
on patients with advanced disease in order to ‘pre-form’
cohorts of characterized patients who can be expe-
ditiously directed towards appropriate studies when the
time is right. Outside of the academic setting, however,
patients may have limited geographic and financial
access to trials, and it is not clear that it is helpful to
them to learn about a study that they cannot travel to or
afford. An alternative would be to conduct limited
genomic characterization to determine eligibility for
studies that are practical for the specific circumstance,
rather than broad profiling.
In summary, then, somatic mutation profiling by NGS is
not necessary for deployment of approved genomically-
directed treatments and is not yet at the point where it
can be used to direct off-protocol treatment. Profiling may
be useful as a screening tool to determine trial eligibility
but, for most patients, it may be more practical to employ
a more limited approach to determine eligibility for
specific studies of interest to the particular individual,
given their clinical circumstances.
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